Study explores eye health after COVID-19 recovery through the choroidal vascularity index

News
Article

A total of 43 patients who recovered from the SARS-CoV-2 infection with mild pneumonia were included along with 45 healthy individuals.

Physician using stethoscope on patient Image credit: AdobeStock/joyfotoliakid

Image credit: AdobeStock/joyfotoliakid

Researchers from Istanbul, Turkey, conducted a study that found that the choroidal vascularity index (CVI) can shed light on the choroidal vascular physiology in patients who had had mild COVID-19 pneumonia and recovered completely,1 reported Muge Toprak, MD, and colleagues. Toprak is from the Kocaeli City Hospital, Istanbul. They published their findings in International Ophthalmology.

A total of 43 patients who recovered from the SARS-CoV-2 infection with mild pneumonia (group 1, COVID group) were included along with 45 healthy individuals (group 2, healthy control group).

All fully recovered patients were evaluated 6 months after the pneumonia resolved. The investigators measured the choroidal structures using enhanced depth imaging optical coherence tomography (EDI-OCT). The primary measurement of interest was the CVI, which the investigators defined as the ratio of the luminal area to the total choroidal area.

The patients who comprised group 1 (COVID group) had significantly higher values compared to the healthy group 2 controls in the mean total choroidal area, the stromal area, and the luminal area. There was no difference in the CVI between the 2 groups (p = 0.080).

Based on their findings, the investigators concluded that the CVI can reveal the choroidal vascular physiology in patients who have fully recovered from COVID-19 pneumonia. The EDI-OCT technology can be used to evaluate choroidal vascular alterations and thereby serve as a non-invasive indicator for early vascular impairment following SARS-CoV-2 infection.

Reference:
  1. Toprak M, Kesim E, Karasu B, Celebi ARC. Choroidal vascularity index findings in patients recovered from mild course COVID-19 pneumonia.Int Ophthalmol. 2025;45:84. https://doi.org/10.1007/s10792-025-03450-4

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
© 2025 MJH Life Sciences

All rights reserved.